Many studies have observed that anti-VEGF agents promote the accumulation of CD8+ and CD4+ T lymphocytes in tumors, decrease PD-1 expression of tumor-infiltrating T lymphocytes and inhibit regulatory T cells as well as myeloid-derived suppressor cells and their immunosuppressive functions (23–25). This evidence concerns the gene CD8A and neoplasm.